Phase 2 Trial
Neurocrine, Takeda Look to Build on Positives Post Luvadaxistat’s Schizophrenia Trial Failure
2021-03-03
Gilead and Novo Nordisk Present Proof-of-Concept Data for the First Possible NASH Treatment
2020-11-17
Lilly’s Investigational Monoclonal Antibody Registers Symptom Improvement in Crohn’s Disease Patients
2020-10-13
ASCO 2020: Genentech’s Novel anti-TIGIT Therapy Shows Promise in Phase II Lung Cancer Trials
2020-05-31
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115